Knight Pharmaceuticals Private Limited
About Knight Pharmaceuticals Private Limited
Data last updated:
Knight Pharmaceuticals Private Limited is a private limited company based in Virar, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 11 January 2002 and has been in existence for over 24 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51397MH2002PTC134531.
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹2 Lakh. It is led by directors Rahul Manoharrao Hingnekar (Whole-Time Director) and Pallavi Rahul Hingnekar.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at 147/6 Nagasai Apartment Shirgaon Road Chandansar Road Virar Ea, St, Maharashtra, India – 401305.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.09 Cr, a growth of 1% compared to the previous year. For the same year it recorded a net profit of ₹2.87 Lakh (net margin 1.4%) and EBITDA of ₹4.26 Lakh (EBITDA margin 2%). Revenue has declined at a compounded annual rate (CAGR) of 5% over three years.
The company has about 14 employees on its provident fund (EPFO) records.
As per MCA filings, the company has open charges of ₹43.5 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Knight Pharmaceuticals Private Limited's registered office is in Virar, Maharashtra. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address147/6 Nagasai Apartment Shirgaon Road Chandansar Road Virar Ea, St, Maharashtra, India – 401305
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Knight Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Knight Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Knight Pharmaceuticals Private Limited, buy the company report.
Financials of Knight Pharmaceuticals Private Limited
FY 2024 filings availableKnight Pharmaceuticals Private Limited reported revenue of ₹2.09 Cr (up 1% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue rose 1% in the latest year, though over three years it has declined at a compounded annual rate (CAGR) of 5%. EBITDA rose 16% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.26 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹2.87 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2% | ||||
| Net Profit Margin | 1.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Knight Pharmaceuticals Private Limited, buy the company report.
Board of directors of Knight Pharmaceuticals Private Limited
Knight Pharmaceuticals has 2 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pallavi Rahul Hingnekar | Director | 03 Oct 2024 | 2 Years 0 Months | Current |
| Rahul Manoharrao Hingnekar | Whole-Time Director | 11 Jan 2002 | 24 Years 9 Months | Current |
Peer comparison
Knight Pharmaceuticals Private Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Jenome Biophar Private Limited | ₹2.09 Cr (FY 2025) | -50.0% | New Delhi, Delhi, India | |||
| Knight Pharmaceuticals Private Limitedthis company | ₹2.09 Cr (FY 2025) | ₹2.87 Lakh | 1.4% | 1.0% | 14 | Virar, Maharashtra, India |
| Deepodaya Pharmaceuticals Private Limited | ₹2.08 Cr (FY 2025) | -51.0% | Lucknow, Uttar Pradesh, India | |||
| Wellogen Pharma Private Limited | ₹2.08 Cr (FY 2023) | 35.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Knight Pharmaceuticals Private Limited, buy the company report.
Auditor
Knight Pharmaceuticals Private Limited is audited by SAARK & ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SAARK & ASSOCIATES | FY 2023 | 109468 |
Shareholding
The shareholding of Knight Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Knight Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Mar 2018 | 100183575 | Others | ₹43.5 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Knight Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Knight Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Knight Pharmaceuticals Private Limited has a workforce of 14 employees on its EPFO records as of Apr 03, 2024, across 1 active EPFO establishment.
GST
No GST registration is on our record for Knight Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Knight Pharmaceuticals Private Limited has 5 board changes on record since 2002: 2 appointments and 3 cessations. The latest: Pallavi Rahul Hingnekar was appointed as Director on 03 Oct 2024.
Frequently asked questions
Knight Pharmaceuticals is an active private limited company based in Virar, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 11 January 2002 (24+ years old) and is registered under CIN U51397MH2002PTC134531.
Knight Pharmaceuticals has 2 current directors:
- Rahul Manoharrao Hingnekar - Whole-Time Director
- Pallavi Rahul Hingnekar - Director
The latest financial statements of Knight Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Knight Pharmaceuticals is U51397MH2002PTC134531. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Knight Pharmaceuticals was incorporated on 11 January 2002, making it 24+ years old. It is registered with the Registrar of Companies, Mumbai.
The peers of Knight Pharmaceuticals by revenue are Jenome Biophar Private Limited, Deepodaya Pharmaceuticals Private Limited, Wellogen Pharma Private Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (wholesale trading).
Pallavi Rahul Hingnekar was appointed as Director on 03 Oct 2024. Rohini Chandrashekhar Padamagirwar ceased to be Director on 03 Oct 2024. Anita Prafulla Karpe ceased to be Whole-Time Director on 10 Apr 2019. Knight Pharmaceuticals has 5 board changes on record in total.
The registered office of Knight Pharmaceuticals is at 1476 Nagasai Apartment Shirgaon Road Chandansar Road Virar Ea, St, Maharashtra, India – 401305.
Knight Pharmaceuticals operates in the pharma industry, in the drug formulation and development segment.
Knight Pharmaceuticals has open charges of ₹43.5 Lakh and no satisfied charges on record as per latest MCA filings.
The compliance status of Knight Pharmaceuticals is compliant as of 24 August 2026. The company is actively filing with the Registrar of Companies.